Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1961 1
1962 2
1964 7
1965 7
1966 4
1967 4
1968 3
1969 7
1970 7
1971 5
1972 13
1973 14
1974 10
1975 20
1976 28
1977 29
1978 27
1979 19
1980 30
1981 31
1982 28
1983 33
1984 62
1985 61
1986 72
1987 69
1988 72
1989 66
1990 89
1991 104
1992 107
1993 122
1994 102
1995 127
1996 110
1997 135
1998 165
1999 122
2000 125
2001 151
2002 173
2003 178
2004 178
2005 228
2006 231
2007 249
2008 265
2009 300
2010 318
2011 362
2012 384
2013 450
2014 482
2015 564
2016 576
2017 599
2018 592
2019 722
2020 743
2021 837
2022 680
2023 657
2024 258

Text availability

Article attribute

Article type

Publication date

Search Results

10,869 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 3"
Page 1
Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis.
Meyer KC. Meyer KC. Expert Rev Respir Med. 2017 May;11(5):343-359. doi: 10.1080/17476348.2017.1312346. Epub 2017 Apr 10. Expert Rev Respir Med. 2017. PMID: 28345383 Review.
Many forms of interstitial lung disease (ILD) can progress to extensive fibrosis and respiratory failure. Idiopathic pulmonary fibrosis (IPF), which generally has a poor prognosis, has been thoroughly studied over the past two decades, and many …
Many forms of interstitial lung disease (ILD) can progress to extensive fibrosis and respiratory failure. Idiopathic pulmon …
Global incidence and prevalence of idiopathic pulmonary fibrosis.
Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, Patel H, Kreuter M. Maher TM, et al. Respir Res. 2021 Jul 7;22(1):197. doi: 10.1186/s12931-021-01791-z. Respir Res. 2021. PMID: 34233665 Free PMC article. Review.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease with considerable morbidity. ...
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease with considerable morbidity. ...
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Finnerty JP, et al. BMC Pulm Med. 2021 Dec 11;21(1):411. doi: 10.1186/s12890-021-01783-1. BMC Pulm Med. 2021. PMID: 34895203 Free PMC article.
BACKGROUND: Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of anti-fibrotic therapy (grouping nintedanib and pirfenidone together) in patients with IPF versus p …
BACKGROUND: Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fib …
Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Ley B, Collard HR, King TE Jr. Ley B, et al. Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40. doi: 10.1164/rccm.201006-0894CI. Epub 2010 Oct 8. Am J Respir Crit Care Med. 2011. PMID: 20935110 Review.
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease of unknown etiology. ...The goal of this concise clinical review is to examine and summarize the current data on the clinical course, individual predictors …
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease of unknown etiology. ...The …
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.
Hutchinson J, Fogarty A, Hubbard R, McKeever T. Hutchinson J, et al. Eur Respir J. 2015 Sep;46(3):795-806. doi: 10.1183/09031936.00185114. Epub 2015 May 14. Eur Respir J. 2015. PMID: 25976683 Free article. Review.
As idiopathic pulmonary fibrosis emerges as an important public health problem, there is a need to coordinate data on incidence and mortality globally. ...The majority of studies showed an increase in incidence over time.The incidence of idiopathic pulmonary …
As idiopathic pulmonary fibrosis emerges as an important public health problem, there is a need to coordinate data on incidenc …
Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management.
Luppi F, Kalluri M, Faverio P, Kreuter M, Ferrara G. Luppi F, et al. Respir Res. 2021 Apr 17;22(1):109. doi: 10.1186/s12931-021-01711-1. Respir Res. 2021. PMID: 33865386 Free PMC article. Review.
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with an estimated median survival time of 3-5 years after diagnosis. ...Ageing and senescence, through interactions with environmental factors, may contribute to the pathogenesis of IPF by var …
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with an estimated median survival time of 3-5 years …
Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review.
Shah Gupta R, Koteci A, Morgan A, George PM, Quint JK. Shah Gupta R, et al. BMJ Open Respir Res. 2023 Jun;10(1):e001291. doi: 10.1136/bmjresp-2022-001291. BMJ Open Respir Res. 2023. PMID: 37308252 Free PMC article. Review.
Interstitial lung disease (ILD) is a collective term representing a diverse group of pulmonary fibrotic and inflammatory conditions. Due to the diversity of ILD conditions, paucity of guidance and updates to diagnostic criteria over time, it has been challenging to precise …
Interstitial lung disease (ILD) is a collective term representing a diverse group of pulmonary fibrotic and inflammatory conditions. …
Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis.
Naoi H, Suzuki Y, Mori K, Aono Y, Kono M, Hasegawa H, Yokomura K, Inoue Y, Hozumi H, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Nakamura H, Suda T. Naoi H, et al. Thorax. 2022 Jul;77(7):727-730. doi: 10.1136/thoraxjnl-2021-218281. Epub 2022 Mar 30. Thorax. 2022. PMID: 35354649
Patients with idiopathic pulmonary fibrosis (IPF) are at a high risk of lung cancer (LC). Antifibrotic therapy slows disease progression and possibly prolongs survival. ...
Patients with idiopathic pulmonary fibrosis (IPF) are at a high risk of lung cancer (LC). Antifibrotic therapy slows disease p …
Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Petnak T, et al. Chest. 2021 Nov;160(5):1751-1763. doi: 10.1016/j.chest.2021.06.049. Epub 2021 Jul 2. Chest. 2021. PMID: 34217681
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with significant morbidity and mortality. ...
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with significa …
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators. Vancheri C, et al. Am J Respir Crit Care Med. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC. Am J Respir Crit Care Med. 2018. PMID: 28889759 Clinical Trial.
RATIONALE: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis (IPF), but the disease continues to progress. More data are needed on the safety and efficacy of combination therapy with nintedanib and add-on pirfenidone. ...METHODS: Patie …
RATIONALE: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis (IPF), but the disease continues t …
10,869 results
You have reached the last available page of results. Please see the User Guide for more information.